SG11201901311WA - Triazolopyrazinone derivative useful as a human pde1 inhibitor - Google Patents
Triazolopyrazinone derivative useful as a human pde1 inhibitorInfo
- Publication number
- SG11201901311WA SG11201901311WA SG11201901311WA SG11201901311WA SG11201901311WA SG 11201901311W A SG11201901311W A SG 11201901311WA SG 11201901311W A SG11201901311W A SG 11201901311WA SG 11201901311W A SG11201901311W A SG 11201901311WA SG 11201901311W A SG11201901311W A SG 11201901311WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- indiana
- indianapolis
- company
- eli lilly
- Prior art date
Links
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379372P | 2016-08-25 | 2016-08-25 | |
| PCT/US2017/047479 WO2018039051A1 (en) | 2016-08-25 | 2017-08-18 | Triazolopyrazinone derivative useful as a human pde1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901311WA true SG11201901311WA (en) | 2019-03-28 |
Family
ID=59762063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901311WA SG11201901311WA (en) | 2016-08-25 | 2017-08-18 | Triazolopyrazinone derivative useful as a human pde1 inhibitor |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US10138244B2 (es) |
| EP (1) | EP3504208B1 (es) |
| JP (1) | JP6633246B2 (es) |
| KR (1) | KR20190028544A (es) |
| CN (1) | CN109641902B (es) |
| AR (1) | AR109328A1 (es) |
| AU (1) | AU2017317111A1 (es) |
| BR (1) | BR112019000988A2 (es) |
| CA (1) | CA3034828A1 (es) |
| CL (1) | CL2019000487A1 (es) |
| CO (1) | CO2019001644A2 (es) |
| CR (1) | CR20190078A (es) |
| CY (1) | CY1123406T1 (es) |
| DK (1) | DK3504208T3 (es) |
| DO (1) | DOP2019000021A (es) |
| EA (1) | EA201990313A1 (es) |
| EC (1) | ECSP19013196A (es) |
| ES (1) | ES2800433T3 (es) |
| HR (1) | HRP20201187T1 (es) |
| HU (1) | HUE050419T2 (es) |
| JO (1) | JOP20170164A1 (es) |
| LT (1) | LT3504208T (es) |
| MA (1) | MA46039B1 (es) |
| MD (1) | MD3504208T2 (es) |
| ME (1) | ME03791B (es) |
| MX (1) | MX2019002065A (es) |
| PE (1) | PE20190452A1 (es) |
| PH (1) | PH12019500370A1 (es) |
| PL (1) | PL3504208T3 (es) |
| PT (1) | PT3504208T (es) |
| RS (1) | RS60442B1 (es) |
| SG (1) | SG11201901311WA (es) |
| SI (1) | SI3504208T1 (es) |
| SV (1) | SV2019005838A (es) |
| TN (1) | TN2019000038A1 (es) |
| TW (1) | TWI651323B (es) |
| WO (1) | WO2018039051A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR112457A1 (es) | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
| TW201920188A (zh) | 2017-08-10 | 2019-06-01 | 美商美國禮來大藥廠 | [1,2,4]三唑衍生物 |
| US11453673B2 (en) | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
| EP4017858A4 (en) * | 2019-08-22 | 2023-09-27 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| WO2025059641A1 (en) | 2023-09-14 | 2025-03-20 | Eli Lilly And Company | Pde1 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4354027A (en) | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
| ES2599054T3 (es) * | 2006-12-13 | 2017-01-31 | Aska Pharmaceutical Co., Ltd. | Derivados de quinoxalina |
| WO2008103357A1 (en) | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
| WO2012033101A1 (ja) | 2010-09-07 | 2012-03-15 | アステラス製薬株式会社 | キノキサリン化合物 |
| IN2015DN00334A (es) | 2012-06-18 | 2015-06-12 | Dart Neuroscience Cayman Ltd | |
| US9938284B2 (en) * | 2014-08-07 | 2018-04-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US20160083400A1 (en) * | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| TW201629064A (zh) * | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| AR107456A1 (es) * | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
-
2016
- 2016-08-25 JO JOP/2017/0164A patent/JOP20170164A1/ar unknown
-
2017
- 2017-08-11 TW TW106127199A patent/TWI651323B/zh not_active IP Right Cessation
- 2017-08-11 AR ARP170102252A patent/AR109328A1/es unknown
- 2017-08-18 US US15/680,250 patent/US10138244B2/en active Active
- 2017-08-18 CN CN201780050004.2A patent/CN109641902B/zh active Active
- 2017-08-18 SG SG11201901311WA patent/SG11201901311WA/en unknown
- 2017-08-18 EP EP17761381.7A patent/EP3504208B1/en active Active
- 2017-08-18 CR CR20190078A patent/CR20190078A/es unknown
- 2017-08-18 SI SI201730305T patent/SI3504208T1/sl unknown
- 2017-08-18 ME MEP-2020-144A patent/ME03791B/me unknown
- 2017-08-18 BR BR112019000988-4A patent/BR112019000988A2/pt not_active IP Right Cessation
- 2017-08-18 HR HRP20201187TT patent/HRP20201187T1/hr unknown
- 2017-08-18 CA CA3034828A patent/CA3034828A1/en not_active Abandoned
- 2017-08-18 HU HUE17761381A patent/HUE050419T2/hu unknown
- 2017-08-18 MA MA46039A patent/MA46039B1/fr unknown
- 2017-08-18 JP JP2019510969A patent/JP6633246B2/ja active Active
- 2017-08-18 TN TNP/2019/000038A patent/TN2019000038A1/en unknown
- 2017-08-18 PT PT177613817T patent/PT3504208T/pt unknown
- 2017-08-18 RS RS20200738A patent/RS60442B1/sr unknown
- 2017-08-18 MX MX2019002065A patent/MX2019002065A/es unknown
- 2017-08-18 PE PE2019000371A patent/PE20190452A1/es unknown
- 2017-08-18 PL PL17761381T patent/PL3504208T3/pl unknown
- 2017-08-18 ES ES17761381T patent/ES2800433T3/es active Active
- 2017-08-18 MD MDE20190732T patent/MD3504208T2/ro unknown
- 2017-08-18 AU AU2017317111A patent/AU2017317111A1/en not_active Abandoned
- 2017-08-18 LT LTEP17761381.7T patent/LT3504208T/lt unknown
- 2017-08-18 WO PCT/US2017/047479 patent/WO2018039051A1/en not_active Ceased
- 2017-08-18 EA EA201990313A patent/EA201990313A1/ru unknown
- 2017-08-18 DK DK17761381.7T patent/DK3504208T3/da active
- 2017-08-18 KR KR1020197005013A patent/KR20190028544A/ko not_active Withdrawn
-
2019
- 2019-01-30 DO DO2019000021A patent/DOP2019000021A/es unknown
- 2019-02-19 SV SV2019005838A patent/SV2019005838A/es unknown
- 2019-02-21 PH PH12019500370A patent/PH12019500370A1/en unknown
- 2019-02-22 CO CONC2019/0001644A patent/CO2019001644A2/es unknown
- 2019-02-22 CL CL2019000487A patent/CL2019000487A1/es unknown
- 2019-02-22 EC ECSENADI201913196A patent/ECSP19013196A/es unknown
-
2020
- 2020-08-14 CY CY20201100760T patent/CY1123406T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201901311WA (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201908159QA (en) | Dual magl and faah inhibitors | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |